Olmesartan Medoxomil E Amlodipina Teva (Olmesartan Medoxomil, Amlodipine)

Olmesartan Medoxil / Amlodipine combines two antihypertensive agents that act on the renin‑angiotensin system and vascular smooth‑muscle tone.

• Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient.
• Chronic kidney disease with hypertension: helps achieve target blood‑pressure goals to slow renal decline.
• Heart failure with reduced ejection fraction (as adjunct therapy): contributes to afterload reduction and symptom control.
• Post‑myocardial infarction hypertension: assists in secondary prevention by maintaining optimal blood pressure.
• Elderly patients with isolated systolic hypertension: offers effective systolic pressure lowering with a favorable tolerability profile.

• Olmesartan medoxomil is a selective antagonist of the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium‑channel blocker that inhibits calcium influx into vascular smooth‑muscle cells, producing arterial vasodilation. The combination yields complementary reductions in systemic vascular resistance and blood pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or lower legs.
• Dizziness or light‑headedness, especially after the first doses.
• Flushing: transient warmth and reddening of the skin.
• Fatigue: general feeling of tiredness.
• Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue or airway.
• Severe hypotension: symptomatic low blood pressure requiring medical attention.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Acute kidney injury: sudden decline in renal function.
• Cardiac arrhythmias: irregular heart rhythms.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Before initiating therapy, clinicians should evaluate patient history and comorbid conditions.

• Renal impairment: adjust dose and monitor serum creatinine.
• Hepatic disease: use with caution; monitor liver function tests.
• Electrolyte disturbances: check potassium and sodium levels regularly.
• Concomitant diuretics: assess for additive blood‑pressure lowering effects.
• Pregnancy: contraindicated in the second and third trimesters; avoid use.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light, retain in original packaging.

Olmesartan Medoxil / Amlodipine may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal impairment.
• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine plasma concentrations.
• Lithium: may increase lithium levels, risking toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Potassium‑sparing diuretics or supplements: monitor serum potassium.
• Antidiabetic agents: possible enhancement of glucose‑lowering effect.
• Rifampicin: may reduce amlodipine concentrations, requiring dose adjustment.